dr. sequist on rationale for tatton trial in egfr-mutant lung cancer
Published 5 years ago • 383 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
4:50
tatton: phase 1b trial of azd9291 for egfr-mutant lung cancer
-
4:49
tatton trial – savolitinib plus osimertinib in egfr-mutated, met-amplified nsclc | lecia sequist
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
1:26
dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
-
9:25
tatton: updated results for patients with egfr-mutant positive nsclc
-
4:46
tatton: phase 1b trial of combination therapies with azd9291 in egfr-mutant lung cancer
-
2:30
tatton: osimertinib plus savolitinib for patients with egfr-mutant, met-amplified nsclc after pr...
-
1:05
dr. sequist on frontline egfr tki use in nsclc
-
1:03
dr. sequist discusses combination regimens in egfr nsclc
-
4:09
frontline afatinib in egfr-mutant nsclc
-
0:55
dr. sequist discusses the efficacy of co-1686 for nsclc
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
2:25
dr. sequist discusses the os analysis of lux-lung 3 and lux-lung 6
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
45:43
egfr mutant lung cancer: 2013 update
-
3:08
recommended mutation testing in lung cancer